Metabolic and clinical consequences of hyperthyroidism on bone density

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Gorka, Jagoda ^a   Taylor Gjevre, Regina M ^a   Arnason, Terra ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTITHYROID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; ESTROGEN; LEVOTHYROXINE; PAMIDRONIC ACID; PLACEBO; RADIOACTIVE IODINE; RISEDRONIC ACID; THIAMAZOLE; THIAZIDE DIURETIC AGENT; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROTROPIN; THYROXINE; VITAMIN D;

BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL (TOPIC); CORTICAL BONE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; FRACTURE; HORMONE ACTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MINERAL METABOLISM; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEX DIFFERENCE; SUBCLINICAL HYPERTHYROIDISM; THYROID FUNCTION; THYROTOXICOSIS; TOXIC GOITER; TRABECULAR BONE;

EID: 84881401204     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/638727     Document Type: Review

References (112)

1. Gennari C., Martini G., Nuti R., Secondary osteoporosis. Aging 1998 10 3 214 224 2-s2.0-0031717111
2. Bassett J. H. D., Williams G. R., The molecular actions of thyroid hormone in bone. Trends in Endocrinology and Metabolism 2003 14 8 356 364 2-s2.0-0141895078 10.1016/S1043-2760(03)00144-9 (Pubitemid 37236956)
3. Bianco A. C., Salvatore D., Gereben B., Berry M. J., Larsen P. R., Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 2002 23 1 38 89 2-s2.0-0036191639 10.1210/er.23.1.38 (Pubitemid 34185306)
4. Wexler J. A., Sharretts J., Thyroid and bone. Endocrinology and Metabolism Clinics of North America 2007 36 3 673 705 2-s2.0-34547300704 10.1016/j.ecl.2007.04.005 (Pubitemid 47135589)
5. Harvey C. B., Bassett J. H. D., Maruvada P., Yen P. M., Williams G. R., The rat thyroid hormone receptor (TR) Deltabeta3 displays cell-, TR isoform-, and thyroid hormone response element-specific actions. Endocrinology 2007 148 4 1764 1773 2-s2.0-33947408056 10.1210/en.2006-1248 (Pubitemid 46457139)
6. Murphy E., Williams G. R., The thyroid and the skeleton. Clinical Endocrinology 2004 61 3 285 298 2-s2.0-4644231760 10.1111/j.1365-2265.2004. 02053.x (Pubitemid 39287057)
7. O'Shea P. J., Harvey C. B., Suzuki H., Kaneshige M., Kaneshige K., Cheng S., Williams G. R., A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Molecular Endocrinology 2003 17 7 1410 1424 2-s2.0-0037633770 10.1210/me.2002-0296 (Pubitemid 36819960)
8. O'Shea P. J., Bassett J. H. D., Sriskantharajah S., Ying H., Cheng S., Williams G. R., Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor α 1 or β Molecular Endocrinology 2005 19 12 3045 3059 2-s2.0-28144460153 10.1210/me.2005-0224 (Pubitemid 41697720)
9. Bassett J. H. D., Williams G. R., The skeletal phenotypes of TR α and TB β mutant mice. Journal of Molecular Endocrinology 2009 42 4 269 282 2-s2.0-67449123453 10.1677/JME-08-0142
10. Gauthier K., Plateroti M., Harvey C. B., Williams G. R., Weiss R. E., Refetoff S., Willott J. F., Sundin V., Roux J.-P., Malaval L., Hara M., Samarut J., Chassande O., Genetic analysis reveals different functions for the products of the thyroid hormone receptor α locus. Molecular and Cellular Biology 2001 21 14 4748 4760 2-s2.0-0034955661 10.1128/MCB.21.14.4748-4760.2001 (Pubitemid 32588255)
11. Bassett J. H. D., Nordström K., Boyde A., Howell P. G. T., Kelly S., Vennström B., Williams G. R., Thyroid status during skeletal development determines adult bone structure and mineralization. Molecular Endocrinology 2007 21 8 1893 1904 2-s2.0-34547413046 10.1210/me.2007-0157 (Pubitemid 47173799)
12. Grimnes G., Emaus N., Joakimsen R. M., Figenschau Y., Jorde R., The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study. Thyroid 2008 18 11 1147 1155 2-s2.0-56549111013 10.1089/thy.2008.0158
13. Lee W. Y., Oh K. W., Rhee E. J., Jung C. H., Kim S. W., Yun E. J., Tae H. J., Baek K. H., Kang M. I., Choi M. G., Yoo H. J., Park S. W., Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Archives of Medical Research 2006 37 4 511 516 2-s2.0-33646044357 10.1016/j.arcmed.2005.09.009
14. Foldes J., Tarjan G., Szathmari M., Varga F., Krasznai I., Horvath C., Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clinical Endocrinology 1993 39 5 521 527 2-s2.0-0027434963 (Pubitemid 23323948)
15. Abe E., Marians R. C., Yu W., Wu X., Ando T., Li Y., Iqbal J., Eldeiry L., Rajendren G., Blair H. C., Davies T. F., Zaidi M., TSH is a negative regulator of skeletal remodeling. Cell 2003 115 2 151 162 2-s2.0-10744226715 10.1016/S0092-8674(03)00771-2 (Pubitemid 37329579)
16. Tsai J. A., Janson A., Bucht E., Kindmark H., Marcus C., Stark A., Zemack H. R., Torring O., Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-like cells. Calcified Tissue International 2004 74 5 486 491 2-s2.0-2442505089 10.1007/s00223-003-0108-3 (Pubitemid 38623635)
17. Davies T., Marians R., Latif R., The TSH receptor reveals itself. Journal of Clinical Investigation 2002 110 2 161 164 2-s2.0-0036070856 10.1172/JCI200216234 (Pubitemid 34787352)
18. Sun L., Davies T. F., Blair H. C., Abe E., Zaidi M., TSH and bone loss. Annals of the New York Academy of Sciences 2006 1068 1 309 318 2-s2.0-33744721035 10.1196/annals.1346.033 (Pubitemid 43824162)
19. Morimura T., Tsunekawa K., Kasahara T., Seki K., Ogiwara T., Mori M., Murakami M., Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005 146 4 2077 2084 2-s2.0-15444374843 10.1210/en.2004-1432 (Pubitemid 40396919)
20. Raggatt L. J., Partridge N. C., Cellular and molecular mechanisms of bone remodeling. Journal of Biological Chemistry 2010 285 33 25103 25108 2-s2.0-77955497814 10.1074/jbc.R109.041087
21. Lee M. S., Kim S. Y., Lee M. C., Cho B. Y., Lee H. K., Koh C.-S., Min H. K., Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1990 70 3 766 770 2-s2.0-0025278627
22. Fallon M. D., Perry H. M. III, Bergfeld M., Exogenous hyperthyroidism with osteoporosis. Archives of Internal Medicine 1983 143 3 442 444 2-s2.0-0020701820 10.1001/archinte.143.3.442 (Pubitemid 13156431)
23. Fraser S. A., Anderson J. B., Smith D. A., Wilson G. M., Osteoporosis and fractures following thyrotoxicosis. The Lancet 1971 1 7707 981 983 2-s2.0-0015225556
24. Eriksen E. F., Mosekilde L., Melsen F., Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 1985 6 6 421 428 2-s2.0-0022411495 (Pubitemid 16184793)
25. Melsen F., Mosekilde L., Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions. Acta Pathologica et Microbiologica Scandinavica A 1980 88 2 83 88 2-s2.0-0018837286 (Pubitemid 10155343)
26. Mosekilde L., Eriksen E. F., Charles P., Effects of thyroid hormones on bone and mineral metabolism. Endocrinology and Metabolism Clinics of North America 1990 19 1 35 63 2-s2.0-0025308220 (Pubitemid 20142107)
27. Harvey C. B., O'Shea P. J., Scott A. J., Robson H., Siebler T., Shalet S. M., Samarut J., Chassande O., Williams G. R., Molecular mechanisms of thyroid hormone effects on bone growth and function. Molecular Genetics and Metabolism 2002 75 1 17 30 2-s2.0-0036354280 10.1006/mgme.2001.3268 (Pubitemid 34971531)
28. Frizel D., Malleson A., Marks V., Plasma levels of ionised calcium and magnesium in thyroid disease. The Lancet 1967 1 7504 1360 1361 2-s2.0-0014215648
29. Jastrup B., Mosekilde L., Melsen F., Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism. Metabolism 1982 31 2 126 132 2-s2.0-0020041585 (Pubitemid 12222526)
30. Karsenty G., Bouchard P., Ulmann A., Schaison G., Elevated metabolic clearance rate of 1 α25-dihydroxyvitamin D3 in hyperthyroidism. Acta Endocrinologica 1985 110 1 70 74 2-s2.0-0021930083 (Pubitemid 15240688)
31. Thomas F. B., Caldwell J. H., Greenberger N. J., Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Annals of Internal Medicine 1973 78 5 669 675 2-s2.0-0015619808
32. Park S. E., Cho M. A., Kim S. H., Rhee Y., Kang E. S., Ahn C. W., Cha B. S., Lee E. J., Kim K. R., Lee H. C., Lim S., The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease. Clinical Endocrinology 2007 66 6 854 858 2-s2.0-34347378695 10.1111/j.1365-2265.2007. 02824.x (Pubitemid 47024273)
33. Garrel D. R., Delmas P. D., Malaval L., Tourniaire J., Serum bone Gla protein: a marker of bone turnover in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1986 62 5 1052 1055 2-s2.0-0022624721 (Pubitemid 16106740)
34. Guo C., Weetman A. P., Eastell R., Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clinical Endocrinology 1997 46 3 301 307 2-s2.0-0030936418 (Pubitemid 27174334)
35. Toivonen J., Tähtelä R., Laitinen K., Risteli J., Välimäki M. J., Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. European Journal of Endocrinology 1998 138 6 667 673 2-s2.0-2642617814 10.1530/eje.0.1380667 (Pubitemid 28313817)
36. Cooper D. S., Kaplan M. M., Ridgway E. C., Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Annals of Internal Medicine 1979 90 2 164 168 2-s2.0-0018349191 (Pubitemid 9117741)
37. Amato G., Mazziotti G., Sorvillo F., Piscopo M., Lalli E., Biondi B., Iorio S., Molinari A., Giustina A., Carella C., High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004 35 3 785 791 2-s2.0-4344560813 10.1016/j.bone.2004.04.021 (Pubitemid 39141881)
38. Harvey R. D., McHardy K. C., Reid I. W., Paterson F., Bewsher P. D., Duncan A., Robins S. P., Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. Journal of Clinical Endocrinology and Metabolism 1991 72 6 1189 1194 2-s2.0-0025744590 (Pubitemid 21921826)
39. MacLeod J. M., McHardy K. C., Harvey R. D., Duncan A., Reid I. W., Bewsher P. D., Robins S. P., The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clinical Endocrinology 1993 38 1 49 53 2-s2.0-0027452608 (Pubitemid 23030273)
40. Vestergaard P., Mosekilde L., Hyperthyroidism, bone mineral, fracture risk-a meta-analysis. Thyroid 2003 13 6 585 593 2-s2.0-0038506905 (Pubitemid 36842665)
41. Chen C.-H., Chen J.-F., Yang B.-Y., Liu R.-T., Tung S.-C., Chien W.-Y., Lu Y., Kuo M., Hsieh C., Wang P., Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. Journal of the Formosan Medical Association 2004 103 6 442 447 2-s2.0-4444324979 (Pubitemid 39302901)
42. Greenspan S. L., Greenspan F. S., The effect of thyroid hormone on skeletal integrity. Annals of Internal Medicine 1999 130 9 750 758 2-s2.0-0033522483 (Pubitemid 29211514)
43. Bianchi G. S., Meunier P., Courpron P., Edouard C., Bernard J., Vignon G., Osseous effects of hyperthyroidism. Revue du Rhumatisme et des Maladies Osteo-Articulaires 1972 39 1 19 32 2-s2.0-0015278667
44. Svare A., Nilsen T. I. L., Bjøro T., Forsmo S., Schei B., Langhammer A., Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. European Journal of Endocrinology 2009 161 5 779 786 2-s2.0-70449722919 10.1530/EJE-09-0139
45. Kosowicz J., Baszko-Błaszyh D., Horst-Sikorska W., Baumann-Antczak A., Bone mineral density in primary hyperparathyroidism. Polskie Archiwum Medycyny Wewnetrznej 1999 101 2 133 138 2-s2.0-0033068376
46. Boonya-Ussadorn T., Punkaew B., Sriassawaamorn N., A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women. Journal of the Medical Association of Thailand 2010 93 supplement 6 S1 S5 2-s2.0-84855516152
47. Linde J., Friis T., Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinologica 1979 91 3 437 448 2-s2.0-0018748637 (Pubitemid 9239685)
48. Morris M. S., The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 2007 40 4 1128 1134 2-s2.0-33847700497 10.1016/j.bone.2006.12.001 (Pubitemid 46386560)
49. Wejda B., Hintze G., Katschinski B., Olbricht T., Benker G., Hip fractures and the thyroid: a case-control study. Journal of Internal Medicine 1995 237 3 241 247 2-s2.0-0028949060
50. Cummings S. R., Nevitt M. C., Browner W. S., Stone K., Fox K. M., Ensrud K. E., Cauley J., Black D., Vogt T. M., Risk factors for hip fracture in white women. New England Journal of Medicine 1995 332 12 767 773 2-s2.0-0028963682 10.1056/NEJM199503233321202
51. Allain T. J., McGregor A. M., Thyroid hormones and bone. Journal of Endocrinology 1993 139 1 9 18 2-s2.0-0027490547 (Pubitemid 23347853)
52. Bauer D. C., Ettinger B., Nevitt M. C., Stone K. L., Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine 2001 134 7 561 568 2-s2.0-0035799398 (Pubitemid 32245317)
53. Vestergaard P., Rejnmark L., Weeke J., Mosekilde L., Fracture risk in patients treated for hyperthyroidism. Thyroid 2000 10 4 341 348 2-s2.0-0034021930 (Pubitemid 30256864)
54. Jódar E., Muñoz-Torres M., Escobar-Jiménez F., Quesada M., Luna J. D., Olea N., Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. Journal of Clinical Endocrinology and Metabolism 1997 82 6 1989 1994 2-s2.0-0031159059 (Pubitemid 127495222)
55. Langdahl B. L., Loft A. G. R., Eriksen E. F., Mosekilde L., Charles P., Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. European Journal of Endocrinology 1996 134 6 702 709 2-s2.0-0029884074 (Pubitemid 26226562)
56. Karga H., Papapetrou P. D., Korakovouni A., Papandroulaki F., Polymeris A., Pampouras G., Bone mineral density in hyperthyroidism. Clinical Endocrinology 2004 61 4 466 472 2-s2.0-6344249466 10.1111/j.1365-2265.2004. 02110.x (Pubitemid 39388485)
57. Lakatos P., Thyroid hormones: beneficial or deleterious for bone? Calcified Tissue International 2003 73 3 205 209 2-s2.0-0141523155 10.1007/s00223-002-0027-8 (Pubitemid 37152879)
58. Siddiqi A., Burrin J. M., Noonan K., James I., Wood D. F., Price C. P., Monson J. P., A longitudinal study of markers of bone turnover in Graves' disease and their value in predicting bone mineral density. Journal of Clinical Endocrinology and Metabolism 1997 82 3 753 759 2-s2.0-0031044494 10.1210/jc.82.3.753 (Pubitemid 27106582)
59. Serraclara A., Jódar E., Sarabia F., Hawkins F., Bone mass after long-term euthyroidism in former hyperthyroid women treated with 131I: influence of menopausal status. Journal of Clinical Densitometry 2001 4 3 249 255 2-s2.0-0034774284 10.1385/JCD:4:3:249 (Pubitemid 32938092)
60. Toh S. H., Claunch B. C., Brown P. H., Effect of hyperthyroidism and its treatment on bone mineral content. Archives of Internal Medicine 1985 145 5 883 886 2-s2.0-0021846223 10.1001/archinte.145.5.883 (Pubitemid 15033254)
61. Diamond T., Vine J., Smart R., Butler P., Thyrotoxic bone disease in women: a potentially reversible disorder. Annals of Internal Medicine 1994 120 1 8 11 2-s2.0-0028153535 (Pubitemid 24011494)
62. Franklyn J., Betteridge J., Holder R., Daykin J., Lilley J., Sheppard M., Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clinical Endocrinology 1994 41 4 425 432 2-s2.0-0028103839 (Pubitemid 24301274)
63. Grant D. J., McMurdo M. E. T., Mole P. A., Paterson C. R., Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clinical Endocrinology 1995 43 3 339 345 2-s2.0-0029089969
64. Greenlund L. J. S., Nair K. S., Brennan M. D., Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocrine Practice 2008 14 8 973 978 2-s2.0-65849357643
65. Udayakumar N., Chandrasekaran M., Rasheed M. H., Suresh R. V., Sivaprakash S., Evaluation of bone mineral density in thyrotoxicosis. Singapore Medical Journal 2006 47 11 947 950 2-s2.0-33750979832 (Pubitemid 44745428)
66. Chen S. T., Huang M. J., Juang J. H., Bone changes in hyperthyroidism-a preliminary study. Changgeng Yi Xue Za Zhi 1990 13 4 274 281
67. Jódar E., Muñoz-Torres M., Escobar-Jiménez F., Quesada-Charneco M., Luna Del Castillo J. D., Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clinical Endocrinology 1997 47 3 279 285 2-s2.0-0030774682 (Pubitemid 27395958)
68. Rosen J., Density B., Adler A., Changes in lumbar of euthyroidism. 1992
69. Murphy E., Bassett J. H. D., Williams G. R., Disorders of calcium. Practitioner 2006 250 1686 4 8 2-s2.0-33749233994 (Pubitemid 44483926)
70. Zeni S., Gomez-Acotto C., Mautalen C., The effect of olpadronate in ovariectomized thyroxine-treated rats. Bone 1997 21 4 329 333 2-s2.0-0030713048 10.1016/S8756-3282(97)00146-4 (Pubitemid 27454086)
71. Lupoli G., Nuzzo V., Di Carlo C., Affinito P., Vollery M., Vitale G., Cascone E., Arlotta F., Nappi C., Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecological Endocrinology 1996 10 5 343 348 2-s2.0-0029907386 (Pubitemid 26364674)
72. Fittipaldi M. R., Fonderico F., Vitale G., Ciccarelli A., Lupoli G. A., Cascella T., Panico A., Lupoli G., Osteoporosis treatment in elderly hyperthyroid male patients. Journal of Endocrinological Investigation 2002 25 10 98 100 2-s2.0-0037638740
73. Majima T., Komatsu Y., Doi K., Takagi C., Shigemoto M., Fukao A., Morimoto T., Corners J., Nakao K., Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. Journal of Bone and Mineral Metabolism 2006 24 2 105 113 2-s2.0-33646479966 10.1007/s00774-005-0655-y
74. Dhanwal D. K., Gupta N., Bone mineral density trends in Indian patients with hyperthyroidism-effect of antithyroid therapy. Journal of Association of Physicians of India 2011 59 9 561 567 2-s2.0-80052666412
75. Cooper D. S., Biondi B., Subclinical thyroid disease. The Lancet 2012 379 9821 1142 1154 2-s2.0-84859104026 10.1016/S0140-6736(11)60276-6
76. Mudde A. H., Houben A. J. H. M., Nieuwenhuijzen Kruseman A. C., Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clinical Endocrinology 1994 41 4 421 424 2-s2.0-0028098795 (Pubitemid 24301273)
77. Cooper D. S., Approach to the patient: approach to the patient with subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2007 92 1 3 9 2-s2.0-33846047562 10.1210/jc.2006-2472 (Pubitemid 46067502)
78. Ugur-Altun B., Altun A., Arikan E., Guldiken S., Tugrul A., Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Endocrine Research 2003 29 4 389 398 2-s2.0-0344736885 10.1081/ERC-120026945 (Pubitemid 37517840)
79. Biondi B., Palmieri A., Klain M., Schlumberger M., Filetti S., Lombardi G., Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology 2005 152 1 1 9 2-s2.0-13244257200 10.1530/eje.1.01809 (Pubitemid 40185448)
80. Gürlek A., Gedik O., Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999 9 6 539 543 2-s2.0-2442736253 (Pubitemid 29296115)
81. Rosen H. N., Moses A. C., Garber J., Ross D. S., Lee S. L., Ferguson L., Chen V., Lee K., Greenspan S. L., Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. Journal of Clinical Endocrinology and Metabolism 1998 83 7 2324 2330 2-s2.0-0031784573 10.1210/jc.83.7.2324 (Pubitemid 28503022)
82. Rosen H. N., Moses A. C., Gundberg C., Kung V. T., Seyedin S. M., Chen T., Holick M., Greenspan S. L., Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. Journal of Clinical Endocrinology and Metabolism 1993 77 3 664 669 2-s2.0-0027375999 10.1210/jc.77.3.664 (Pubitemid 23298645)
83. Kung A. W. C., Yeung S. S., Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. Journal of Clinical Endocrinology and Metabolism 1996 81 3 1232 1236 2-s2.0-0029866430 10.1210/jc.81.3.1232 (Pubitemid 26083997)
84. Tauchmanovà L., Nuzzo V., Del Puente A., Fonderico F., Esposito-Del Puente A., Padulla S., Rossi A., Bifulco G., Lupoli G., Lombardi G., Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 2004 48 3 299 306 2-s2.0-2942691628 10.1016/j.maturitas.2004.02.017 (Pubitemid 38781155)
85. Rosario P. W., Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arquivos Brasileiros de Endocrinologia e Metabologia 2008 52 9 1448 1451 2-s2.0-60149084826 10.1590/S0004-27302008000900007
86. De Menis E., Da Rin G., Roiter I., Legovini P., Foscolo G., Conte N., Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Hormone Research 1992 37 6 217 220 2-s2.0-0027053218 (Pubitemid 23053663)
87. Garton M., Reid I., Loveridge N., Robins S., Murchison L., Beckett G., Reid D., Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clinical Endocrinology 1994 41 6 747 755 2-s2.0-0028608803
88. Lee J. S., Bůžková P., Fink H. A., Vu J., Carbone L., Chen Z., Cauley J., Bauer D. C., Cappola A. R., Robbins J., Subclinical thyroid dysfunction and incident hip fracture in older adults. Archives of Internal Medicine 2010 170 21 1876 1883 2-s2.0-78649682543 10.1001/archinternmed.2010.424
89. Vadiveloo T., Donnan P. T., Cochrane L., Leese G. P., The thyroid epidemiology, audit, and research study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2011 96 5 1344 1351 2-s2.0-79955666598 10.1210/jc.2010-2693
90. Faber J., Galloe A. M., Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. European Journal of Endocrinology 1994 130 4 350 356 2-s2.0-0028296041 (Pubitemid 24135720)
91. Vestergaard P., Mosekilde L., Brixen K., Treatment of osteoporosis with antiresorptive drugs (vitamin D, calcium, estrogen and gestagen, raloxifene, bisphosphonates and calcitonin). Ugeskrift for Laeger 2005 167 8 883 887 2-s2.0-14844286861 (Pubitemid 40341147)
92. Buscemi S., Verga S., Cottone S., Andronico G., D'Orio L., Mannino V., Panzavecchia D., Vitale F., Cerasola G., Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism. Journal of Endocrinological Investigation 2007 30 3 230 235 2-s2.0-34250638653 (Pubitemid 46929323)
93. Faber J., Jensen I. W., Petersen L., Nygaard B., Hegedüs L., Siersbæk-Nielsen K., Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopasual women. Clinical Endocrinology 1998 48 3 285 290 2-s2.0-0031931052 10.1046/j.1365-2265.1998.00427.x (Pubitemid 28137639)
94. Rosario P. W., Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous goiter and its effects on bone metabolism. Arquivos Brasileiros de Endocrinologia & Metabologia 2013 57 2 144 147 10.1590/S0004-27302013000200008
95. Yönem O., Dokmetas H. S., Aslan S. M., Erselcan T., Is antithyroid treatment really relevant for young patients with subclinical hyperthyroidism? Endocrine Journal 2002 49 3 307 314 2-s2.0-0036022450 (Pubitemid 34832301)
96. Parle J. V., Franklyn J. A., Cross K. W., Jones S. C., Sheppard M. C., Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clinical Endocrinology 1991 34 1 77 83 2-s2.0-0026020685
97. Schneider D. L., Barrett-Connor E. L., Morton D. J., Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. Journal of the American Medical Association 1994 271 16 1245 1249 2-s2.0-0028324355 10.1001/jama.271.16.1245 (Pubitemid 24121807)
98. Hanna F. W., Pettit R. J., Ammari F., Evans W. D., Sandeman D., Lazarus J. H., Effect of replacement doses of thyroxine on bone mineral density. Clinical Endocrinology 1998 48 2 229 234 2-s2.0-0031936128 10.1046/j.1365-2265. 1998.00387.x (Pubitemid 28091056)
99. Heemstra K. A., Hamdy N. A. T., Romijn J. A., Smit J. W. A., The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006 16 6 583 591 2-s2.0-33745989237 10.1089/thy.2006.16.583 (Pubitemid 44066265)
100. Cipriani C., Romagnoli E., Scarpiello A., Angelozzi M., Montesano T., Minisola S., Phalangeal quantitative ultrasound and bone mineral density in evaluating cortical bone loss: a study in postmenopausal women with primary hyperparathyroidism and subclinical Iatrogenic hyperthyroidism. Journal of Clinical Densitometry 2009 12 4 456 460 2-s2.0-70350569950 10.1016/j.jocd.2009. 08.002
101. Ross D. S., Neer R. M., Ridgway E. C., Daniels G. H., Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. American Journal of Medicine 1987 82 6 1167 1170 2-s2.0-0023624938
102. Paul T. L., Kerrigan J., Kelly A. M., Braverman L. E., Baran D. T., Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. Journal of the American Medical Association 1988 259 21 3137 3141 2-s2.0-0023890201
103. De Rosa G., Testa A., Giacomini D., Carrozza C., Astazi P., Caradonna P., Prospective study of bone loss in pre- and post-menopausal women on L- thyroxine therapy for non-toxic goitre. Clinical Endocrinology 1997 47 5 529 535 2-s2.0-0030722289 (Pubitemid 27496327)
104. Stock J. M., Surks M. I., Oppenheimer J. H., Replacement dosage of L-thyroxine in hypothyroidism. A re-evaluation. New England Journal of Medicine 1974 290 10 529 533 2-s2.0-0016386456
105. Uzzan B., Campos J., Cucherat M., Nony P., Boissel J. P., Perret G. Y., Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 1996 81 12 4278 4289 2-s2.0-0029801045 10.1210/jc.81.12.4278 (Pubitemid 26412030)
106. Melton L. J. III, Ardila E., Crowson C. S., O'Fallon W. M., Khosla S., Fractures following thyroidectomy in women: a population-based cohort study. Bone 2000 27 5 695 700 2-s2.0-0033761889 10.1016/S8756-3282(00)00379-3
107. Nicholls J. J., Brassill M. J., Williams G. R., Bassett J. H. D., The skeletal consequences of thyrotoxicosis. The Journal of Endocrinology 2012 213 209 221 10.1530/JOE-12-0059
108. Quan M. L., Pasieka J. L., Rorstad O., Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. Journal of Surgical Oncology 2002 79 1 62 69 2-s2.0-0036141006 10.1002/jso.10043 (Pubitemid 34049545)
109. Flynn R. W., Bonellie S. R., Jung R. T., MacDonald T. M., Morris A. D., Leese G. P., Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology and Metabolism 2010 95 1 186 193 2-s2.0-75149179019 10.1210/jc.2009-1625
110. Appetecchia M., Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study. Hormone Research 2005 64 6 293 298 2-s2.0-28744441891 10.1159/000089489 (Pubitemid 41758649)
111. Christiansen C., Lindsay R., Estrogens, bone loss and preservation. Osteoporosis International 1990 1 1 7 13 10.1007/BF01880410
112. Anderson G. L., Limacher M., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. Journal of the American Medical Association 2004 291 14 1701 1712 2-s2.0-1842867053 10.1001/jama.291.14.1701 (Pubitemid 38489892)